Core A: Administration oversees the entire DIAN project: coordinating activities of the other Cores and subcontractors, managing and supporting the DIAN Steering Committee, interacting with the NIAs scientific and administrative liaisons, and managing financial affairs overall and with individual clinical sites. It is led by John C. Morris, with the assistance of Drs. David Holtzman, Alison Goate, Randall Bateman, Virginia Buckles, and Krista Moulder. DIAN was designed to establish an international, multisite collaborative study using comprehensive, intensive, uniform, standardized protocols in a rare group of participants at risk for autosomal dominant Alzheimers disease (ADAD). Its protocols harmonize imaging and biomarker procedures with the Alzheimers Disease Neuroimaging Initiative (ADNI) and clinical and psychometric procedures with the National Alzheimers Coordinating Center (NACC) to make future comparisons with sporadic AD possible. To this end Core A: Administration will pursue the following aims: 1. Organize and coordinate activities and communication of the Cores, subcontractors and clinical performance sites toward achieving the stated goals of DIAN, to include administrative and budgetary support and monitoring, and problem solving on a continuous basis. 2. Organize and support the DIAN Steering Committee and the Resource Allocation Review Committee to include arranging meetings, communication and execution of their decisions and recommendations to DIAN components. With Core B: Clinical, organize/coordinate clinical training of personnel at new DIAN sites or new personnel at established DIAN sites. 3. Following Steering Committee direction, and with all DIAN Cores and the Alzheimers Disease Coordinating Study (ADCS), maintain and update protocols;coordinate and monitor participant recruitment and retention;oversee and monitor data and tissue collection and storage. 4. With the Steering Committee, establish policies/procedures regarding: protection of research participants; resource (data, images, tissue) sharing and dissemination;publications;future expansion of DIAN to include other sites and languages (including the accompanying agreements);and potential new research directions. 5. Arrange for annual external review and advice concerning DIAN goals and progress 6. Generate payments to clinical performance sites for DIAN evaluations;arrange and finance genetic counseling/testing services when desired, translate protocol-consents-testing materials, and participant travel. 7. Ensure smooth transition of the leadership of DIAN from Dr. Morris, current Principal Investigator, to Dr. Bateman, Current Leader of the Clinical Core. Dr. Bateman will assume the position of Principal Investigator of DIAN during year 2 of the next budget period and will relinquish his role as Clinical Core Leader;Dr. Morris will become Associate Director of DIAN and Clinical Core Leader.

Public Health Relevance

The Dominantly Inherited Alzheimer Network (DIAN) has demonstrated cross-sectionally the sequence and timing of biomarker and clinical changes in Alzheimers disease due to a causative mutation. It has set the stage for prevention trials and will continue with critical longitudinal analyses in this same cohort. The Administration Core orchestrates this enterprise to meet its goals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Multi-Year Funded Research Project Cooperative Agreement (UF1)
Project #
2UF1AG032438-07
Application #
8869602
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-07-16
Budget End
2019-12-31
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Bateman, Randall J; Benzinger, Tammie L; Berry, Scott et al. (2016) The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement :
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0163669
Soosman, Steffan K; Joseph-Mathurin, Nelly; Braskie, Meredith N et al. (2016) Widespread white matter and conduction defects in PSEN1-related spastic paraparesis. Neurobiol Aging 47:201-209
Lim, Yen Ying; Hassenstab, Jason; Cruchaga, Carlos et al. (2016) BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain 139:2766-2777
Miller-Thomas, Michelle M; Sipe, Adam L; Benzinger, Tammie L S et al. (2016) Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics 36:1147-63
Muenchhoff, Julia; Poljak, Anne; Thalamuthu, Anbupalam et al. (2016) Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's disease. Sci Rep 6:29078
Tang, Mengxuan; Ryman, Davis C; McDade, Eric et al. (2016) Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurol 15:1317-1325
Su, Yi; Blazey, Tyler M; Owen, Christopher J et al. (2016) Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS One 11:e0152082
Jin, Yan; Su, Yi; Zhou, Xiao-Hua et al. (2016) Heterogeneous multimodal biomarkers analysis for Alzheimer's disease via Bayesian network. EURASIP J Bioinform Syst Biol 2016:12
Roe, Catherine M; Barco, Peggy P; Head, Denise M et al. (2016) Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Dis Assoc Disord :

Showing the most recent 10 out of 29 publications